Related Experiment Video
Updated: Apr 27, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
Omalizumab therapy for bullous pemphigoid
Kenneth K Yu1, Ashley B Crew1, Kelly A N Messingham2
1Keck School of Medicine, University of Southern California, Los Angeles, California.
Systemic omalizumab offers therapeutic benefits for bullous pemphigoid (BP) patients, improving disease control and reducing symptoms. This immunoglobulin E (IgE) inhibitor demonstrated positive outcomes with no significant side effects in a small patient group.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Bullous pemphigoid (BP) is a chronic autoimmune blistering disease.
- Current treatments control but do not cure BP, often requiring long-term immunosuppression.
- Omalizumab, an anti-immunoglobulin E (IgE) therapy, is approved for asthma and shows potential in BP pathogenesis.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
